Since 2013, Creoptix has raised more than CHF 15 million. Today, the life sciences startup developing next-generation bioanalytical instruments for drug discovery and development has raised an additional CHF 8 million in the first closing, as part of a Series C financing round to Support Further Growth. Swiss Canto Invest by Zürcher Kantonalbank led the round.
Waters Corporation (NYSE: WAT) and existing private investors participated in the round. The proceeds enable Creoptix to strengthen its commercial operations in Europe as well as in the US and to expand its market presence to meet the growing need for precise bioanalytical instruments.
Creoptix developed and markets Creoptix WAVE systems to study molecular interactions in real-time and is revolutionizing the world of drug discovery. Based on proprietary waveguide interferometry technology, the Creoptix WAVE system offers a level of sensitivity superior to Surface Plasmon Resonance (SPR), with crude sample robustness normally only achieved with plate-based assays. The technology is facilitating new analytical applications such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker and biotherapeutics development.
As part of the round, Robert Schier Investment Director PE/VC Health-Tech at Swisscanto Invest has joined Creoptix's board of directors. He commented: “Creoptix WAVE systems convinces as a mature, robust, versatile and sensitive technology that addresses many existing and novel applications in life sciences. Swisscanto Invest also sees the excellent commercial potential, which has been confirmed by existing customers and increasing revenues this year. Creoptix is a great match for our growth fund and we are proud to be part of an exciting journey.”
(Press release)
Please login or sign up to comment.
Commenting guidelines